首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名：Gastroenterology and hepatology

缩写：

ISSN：1554-7914

e-ISSN：

IF/分区：0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引2416条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Anastomoses for Ileocolonic Resection in Patients With Crohn's Disease [0.03%] 克罗恩病行回肠切除术患者的肠管吻合手术
Fabrizio Michelassi Fabrizio Michelassi
Gastroenterology & hepatology. 2025 Nov;21(11):717-719. DOI: 2025
Exploring Current and Emerging Therapies for Patients With Primary Biliary Cholangitis [0.03%] 原发性胆汁性胆管炎患者当前及新兴疗法探索
Gary R Lichtenstein Gary R Lichtenstein
Gastroenterology & hepatology. 2025 Nov;21(11):672. DOI: 2025
Diagnosis and Management of Portal Vein Thrombosis in Patients With Cirrhosis [0.03%] 肝硬化患者门静脉血栓的诊断和处理
Joseph K Lim Joseph K Lim
Gastroenterology & hepatology. 2025 Nov;21(11):711-714. DOI: 2025
Reduction in Gastrointestinal Visits and Portal Messaging Following Tenapanor Initiation in Patients in Community Gastrointestinal Practices [0.03%] Tenapanor起始后社区胃肠病诊所患者的门诊访问量和门户网站信息传递量的减少
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):6-7. DOI: 2025
Efficacy and Safety of Tenapanor in IBS-C: A Systematic Review and Meta-Analysis [0.03%] Tenapanor治疗IBS-C疗效和安全性的系统评价和 meta 分析
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):4-5. DOI: 2025
Tenapanor Improves Abdominal Bloating Symptoms in Patients With IBS-C Experiencing Moderate-to-Severe Bloating [0.03%] Tenapanor改善IBS-C患者中至重度腹部胀气症状
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):2-3. DOI: 2025
Treatment Satisfaction With Tenapanor: Real-World Survey of Patients With IBS-C [0.03%] Tenapanor的治疗满意度：IBS-C患者的真实世界调查
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):8-9. DOI: 2025
Real-World Safety Analysis of the Constipation-Predominant IBS Treatment Options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor [0.03%] 利那洛肽、鲁比前列酮、普卡那肽和腾喜拉泊治疗便秘性肠易激综合征的现实世界安全性分析
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):9-10. DOI: 2025
Plecanatide Is Efficacious in Women Aged 18 to 40 Years With IBS-C and Bloating: A Pooled Analysis of Two Phase 3, Randomized, Placebo-Controlled Trials [0.03%] 利可君对18至40岁伴有腹胀的肠易激综合征便秘型女性患者有效：两项随机双盲安慰剂对照III期临床研究的汇总分析
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):3-4. DOI: 2025
Exploring the Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation and IBS-C: A Meta-Analysis of Randomized Control Trials [0.03%] 利那洛肽治疗功能性便秘和儿童期肠易激综合征伴便秘的疗效和安全性：随机对照试验的Meta分析研究
Gastroenterology & hepatology. 2025 Nov;21(11 Suppl 8):10. DOI: 2025